Biosimilar Monoclonal Antibodies Market to Reach $4.1bn in 2020

Friday 1 April 2016, Amsterdam

Market Research Report Press Release A new report, now available on ASDReports, forecasts the world market for biosimilar monoclonal antibodies (mAbs) will reach $4.1bn in 2020. That revenue prediction and others appear in Biosimilar Monoclonal Antibodies Market Forecast 2016-2026: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab. This report is published in February 2016. Visiongain is a business information publisher and consultancy in London, UK.

The analysis predicts the global biosimilar mAb industry and market will continue to grow at a CAGR of 46.96% from 2015-2020, driven by the biosimilar rituximab and infliximab submarkets. In 2015, the biosimilar rituximab submarket held the highest proportion, holding a market share of 47.2%. This submarket will grow at a CAGR of 31.47% from 2015-2020 and 8.78% from 2020-2026. However, the biosimilar infliximab submarket will become the leading submarket by 2018 and remain as such until 2026. It will also be the fastest growing submarket from 2015-2020 with a CAGR of 60.59%.

Demand for the market will be fuelled by the discounted price biosimilar mAbs are available for in comparison to their reference products. There is a need for cheaper drugs as healthcare budgets become increasingly strained by growing populations and ageing demographics which are associated with a greater prevalence of cancer, amongst other indications.
Biosimilar Monoclonal Antibodies Market Forecast 2016-2026

Biosimilar Monoclonal Antibodies Market Forecast 2016-2026

Publish date : February 2016
Report code : ASDR-266907
Pages : 203

Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

Global Biosimilar Monoclonal Antibodies Forecast 2018-2028

Publish date : February 2018
Report code : ASDR-446104
Pages : February 2018

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News